>>Signaling Pathways>> Cell Cycle/Checkpoint>> Microtubule/Tubulin>>Cevipabulin fumarate

Cevipabulin fumarate (Synonyms: TTI-237 fumarate)

Catalog No.GC35659

세비파불린 푸마르산염(TTI-237 푸마르산염)은 경구용 미세소관 활성 항종양 화합물이며 인간 종양 세포주에서 세포독성에 대한 IC50이 18-40nM인 튜불린에 대한 [3H]NSC 49842의 결합을 억제합니다.

Products are for research use only. Not for human use. We do not sell to patients.

Cevipabulin fumarate Chemical Structure

Cas No.: 849550-67-0

Size 가격 재고 수량
10mM (in 1mL DMSO)
US$101.00
재고 있음
5mg
US$79.00
재고 있음
10mg
US$135.00
재고 있음
50mg
US$454.00
재고 있음
100mg
US$725.00
재고 있음

Tel:(909) 407-4943 Email: sales@glpbio.com


고객 리뷰

Based on customer reviews.

  • GlpBio Citations

    GlpBio Citations
  • Bioactive Compounds Premium Provider

    Bioactive Compounds Premium Provider

Sample solution is provided at 25 µL, 10mM.

Description Chemical Properties Product Documents Related Products

Cevipabulin fumarate (TTI-237 fumarate) is an oral, microtubule-active, antitumor compound and inhibits the binding of [3H] vinblastine to tubulin, with an IC50 of 18-40 nM for cytotoxicity in human tumor cell line[1][2]. IC50: 18-40 nM (microtubule in human tumor cells)[1].

Cevipabulin (0-50 nM, 72 hours) shows good activity (between 18 and 40 nM IC50 values) on cell lines from ovarian, breast, prostate, and cervical tumors[1].Flow cytometry experiments reveal that, Cevipabulin (TTI-237) at low concentrations (20-40 nM) produces sub-G1 nuclei and, at concentrations above 50 nM, it causes a strong G2-M block[1]. Cell Cytotoxicity Assay[1] Cell Line: Human cancer cell lines (SK-OV-3, MDA-MB-435, MDA-MB-468, LnCaP, and Hela cells).

Cevipabulin (TTI-2370)( 5, 10, 15, and 20 mg/kg, every 4 days for 4 cycles, in mice) is active by i.v. and p.o. administration against human tumor xenografts, showing dose-dependent effects, with good antitumor activity at 20 and 15 mg/kg[1]. Animal Model: Athymic nu/nu female mice implanted s.c. in the flank with 1×107 LoVo human colon adenocarcinoma cells[1].

[1]. Beyer CF, et al. TTI-237: a novel microtubule-active compound with in vivo antitumor activity. Cancer Res. 2008 Apr 1;68(7):2292-300. [2]. Beyer CF, et al. The microtubule-active antitumor compound TTI-237 has both DB01229-like and Leurocristine-like properties. Cancer Chemother Pharmacol. 2009 Sep;64(4):681-9.

리뷰

Review for Cevipabulin fumarate

Average Rating: 5 ★★★★★ (Based on Reviews and 25 reference(s) in Google Scholar.)

5 Star
100%
4 Star
0%
3 Star
0%
2 Star
0%
1 Star
0%
Review for Cevipabulin fumarate

GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.

Required fields are marked with *

You may receive emails regarding this submission. Any emails will include the ability to opt-out of future communications.